What is Selectis Health Inc's earnings per share (EPS)?

Selectis Health Inc (GBCS) reported diluted earnings per share of $-0.34 for fiscal year 2025. This represents a 57.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Selectis Health Inc Financials

GBCS

Source SEC Filings (10-K/10-Q) Updated May 22, 2026 Currency USD FYE December

This page shows Selectis Health Inc (GBCS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GBCS FY2025 2026-05-22

Debt paydown and overhead control are narrowing losses, but short-term obligations still dominate this business's finances.

Across the last few annual periods, revenue was broadly flat while net loss narrowed from -$4.0M to -$1.0M; that points to a cost-base reset rather than a sales-led fix. Even after operating cash flow turned positive at $1.9M, the current ratio was only 0.3x, so better cash conversion has not yet eased the near-term balance-sheet squeeze.

Deleveraging is visible in the capital structure: long-term debt fell from $34.4M to $13.4M, helping reduce the recurring interest load. But liability mix remains tight because current liabilities reached $25.3M against only $7.6M of current assets, leaving little buffer for timing gaps.

Cash conversion improved faster than reported earnings, with $1.9M of operating cash flow alongside a -$1.0M net loss. That matters because capital intensity is modest — capex was just $444K — so once working capital stops absorbing cash, liquidity can improve without a big rise in revenue.

Financial Health Signals

Financial Profile 12/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Selectis Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Selectis Health Inc has an operating margin of -3.8%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 3/100, suggesting thin profitability after operating expenses. This is up from -6.9% the prior year.

Growth

Selectis Health Inc's revenue grew a modest 4.9% year-over-year to $41.4M. This slow but positive growth earns a score of 44/100.

Leverage

Selectis Health Inc has elevated debt relative to equity (D/E of -2.16), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Selectis Health Inc's current ratio of 0.30 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Selectis Health Inc's free cash flow margin of 3.5% results in a low score of 26/100. Capital expenditures of $444K absorb a large share of operating cash flow.

Piotroski F-Score Strong

7/9

Selectis Health Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-1.85x

For every $1 of reported earnings, Selectis Health Inc generates $-1.85 in operating cash flow ($1.9M OCF vs -$1.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-0.9x

Selectis Health Inc earns $-0.9 in operating income for every $1 of interest expense (-$1.6M vs $1.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.4M

YoY+4.9%

5Y CAGR+14.6%

Selectis Health Inc generated $41.4M in revenue in fiscal year 2025. This represents an increase of 4.9% from the prior year.

EBITDA

-$90K

YoY+92.2%

Selectis Health Inc's EBITDA was -$90K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 92.2% from the prior year.

Net Income

-$1.0M

YoY+58.1%

Selectis Health Inc reported -$1.0M in net income in fiscal year 2025. This represents an increase of 58.1% from the prior year.

EPS (Diluted)

$-0.34

YoY+57.5%

Selectis Health Inc earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 57.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.4M

YoY+177.3%

5Y CAGR-3.8%

Selectis Health Inc generated $1.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 177.3% from the prior year.

Cash & Debt

$1.0M

YoY+48.7%

5Y CAGR-22.3%

10Y CAGR+30.4%

Selectis Health Inc held $1.0M in cash against $13.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.0%

Selectis Health Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-3.8%

YoY+3.1pp

5Y CAGR-19.9pp

Selectis Health Inc's operating margin was -3.8% in fiscal year 2025, reflecting core business profitability. This is up 3.1 percentage points from the prior year.

Net Margin

-2.5%

YoY+3.7pp

5Y CAGR-16.6pp

Selectis Health Inc's net profit margin was -2.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$444K

YoY+1130.1%

5Y CAGR-14.8%

10Y CAGR-2.9%

Selectis Health Inc invested $444K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1130.1% from the prior year.

GBCS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$41.4M+4.9%	$39.5M+7.4%	$36.8M-9.4%	$40.6M+38.6%	$29.3M+39.9%	$20.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$8.9M-3.9%	$9.2M-7.2%	$10.0M+26.7%	$7.9M+33.1%	$5.9M+183.0%	$2.1M
Operating Income	-$1.6M+42.7%	-$2.7M+69.5%	-$9.0M-3026.8%	-$287K+60.7%	-$729K-121.6%	$3.4M
Interest Expense	$1.7M-15.7%	$2.0M-5.8%	$2.2M-2.6%	$2.2M-10.7%	$2.5M+16.7%	$2.1M
Income Tax	$800	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.0M+58.1%	-$2.4M+39.0%	-$4.0M-65.7%	-$2.4M-6.4%	-$2.3M-176.2%	$3.0M
EPS (Diluted)	$-0.34+57.5%	$-0.80+38.9%	$-1.31-65.8%	$-0.79+3.7%	$-0.82	$0.95

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$7.2M-25.8%	$9.7M-10.8%	$10.8M+3.8%	$10.4M-0.4%	$10.5M+0.9%	$10.4M+3.8%	$10.0M+4.5%	$9.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.1M-0.6%	$2.1M-0.2%	$2.1M-4.0%	$2.2M-5.4%	$2.4M+4.3%	$2.3M-5.4%	$2.4M-1.1%	$2.4M
Operating Income	-$1.3M-219.1%	-$396K-33.2%	-$297K+34.1%	-$450K-6.8%	-$422K-333.6%	-$97K+91.7%	-$1.2M-53.4%	-$764K
Interest Expense	$924K+22.9%	$752K+265.5%	$206K-9.0%	$226K-58.4%	$543K+52.6%	$356K-25.1%	$475K-18.9%	$586K
Income Tax	$410K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$6.5M+911.6%	-$804K-206.9%	$752K+344.3%	-$308K+53.0%	-$656K-13.8%	-$576K+64.1%	-$1.6M-302.3%	$794K
EPS (Diluted)	$1.90	N/A	$0.24+340.0%	$-0.10+54.5%	$-0.22	N/A	$-0.52-300.0%	$0.26

GBCS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$32.6M-2.6%	$33.4M-17.8%	$40.7M-4.3%	$42.5M-9.4%	$46.9M+2.2%	$45.9M
Current Assets	$7.6M+114.8%	$3.5M-28.8%	$5.0M-0.1%	$5.0M-37.7%	$8.0M+28.4%	$6.2M
Cash & Equivalents	$1.0M+48.7%	$680K-54.2%	$1.5M+4.5%	$1.4M-63.9%	$3.9M+10.4%	$3.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.3M-13.0%	$2.6M+25.1%	$2.1M-28.0%	$2.9M-17.2%	$3.5M+81.5%	$1.9M
Goodwill	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M
Total Liabilities	$38.8M-0.2%	$38.9M-10.9%	$43.6M+5.1%	$41.5M-5.2%	$43.8M+2.6%	$42.7M
Current Liabilities	$25.3M+28.8%	$19.6M+8.2%	$18.1M+165.0%	$6.8M-41.9%	$11.8M-50.1%	$23.6M
Long-Term Debt	$13.4M-29.9%	$19.1M-24.0%	$25.2M-26.8%	$34.4M+10.8%	$31.1M+64.9%	$18.8M
Total Equity	-$6.2M-14.8%	-$5.4M-82.5%	-$3.0M-411.1%	$953K-69.3%	$3.1M-9.1%	$3.4M
Retained Earnings	-$21.2M-5.2%	-$20.2M-13.8%	-$17.7M-29.1%	-$13.7M-21.4%	-$11.3M-25.3%	-$9.0M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$30.0M-7.9%	$32.6M-2.1%	$33.3M-1.1%	$33.6M-2.6%	$34.5M+3.3%	$33.4M-1.4%	$33.9M-7.6%	$36.7M
Current Assets	$9.8M+29.5%	$7.6M+91.7%	$4.0M-1.2%	$4.0M-15.6%	$4.7M+34.4%	$3.5M-0.1%	$3.5M-41.1%	$6.0M
Cash & Equivalents	$1.3M+27.2%	$1.0M+142.5%	$417K-25.5%	$560K-56.5%	$1.3M+89.4%	$680K-62.7%	$1.8M-43.4%	$3.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.5M+9.3%	$2.3M-28.7%	$3.2M+5.0%	$3.0M+5.8%	$2.9M+9.9%	$2.6M+37.4%	$1.9M-13.0%	$2.2M
Goodwill	$379K-64.8%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M
Total Liabilities	$29.8M-23.3%	$38.8M-0.3%	$38.9M-2.8%	$40.0M-1.5%	$40.6M+4.5%	$38.9M+0.2%	$38.8M-3.0%	$39.9M
Current Liabilities	$16.3M-35.4%	$25.3M+24.5%	$20.3M-4.4%	$21.2M-1.3%	$21.5M+9.6%	$19.6M-2.8%	$20.2M+10.6%	$18.3M
Long-Term Debt	$13.3M-0.6%	$13.4M-27.6%	$18.5M-1.0%	$18.7M-1.6%	$19.0M-0.7%	$19.1M+3.6%	$18.5M-14.5%	$21.6M
Total Equity	$258K+104.2%	-$6.2M-9.9%	-$5.7M+11.6%	-$6.4M-5.2%	-$6.1M-12.4%	-$5.4M-11.9%	-$4.8M-50.2%	-$3.2M
Retained Earnings	-$14.7M+30.7%	-$21.2M-4.0%	-$20.4M+3.5%	-$21.2M-1.5%	-$20.9M-3.3%	-$20.2M-2.9%	-$19.6M-9.0%	-$18.0M

GBCS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.9M+203.2%	-$1.8M-440.0%	$537K+275.9%	-$305K-12.6%	-$271K-109.9%	$2.7M
Capital Expenditures	$444K+1130.1%	$36K+21.0%	$30K-86.6%	$222K-57.2%	$520K-47.3%	$986K
Free Cash Flow	$1.4M+177.3%	-$1.9M-467.1%	$507K+196.1%	-$528K+33.3%	-$791K-145.2%	$1.7M
Investing Cash Flow	-$444K-118.1%	$2.4M+8315.9%	-$30K+86.6%	-$222K+57.2%	-$520K+67.0%	-$1.6M
Financing Cash Flow	-$977K+36.5%	-$1.5M-148.4%	-$619K+66.5%	-$1.8M-215.2%	$1.6M-12.0%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$102K

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.3M-455.6%	$644K+130.0%	$280K+461.9%	-$77K-107.5%	$1.0M+344.6%	-$423K+65.5%	-$1.2M-190.3%	-$423K
Capital Expenditures	$377K+566.2%	$57K+1237.7%	$4K-97.4%	$164K-25.4%	$219K+2129.0%	$10K+1649.0%	-$635+99.3%	-$90K
Free Cash Flow	-$2.7M-554.1%	$587K+113.0%	$276K+214.5%	-$241K-129.5%	$816K+288.4%	-$433K+64.7%	-$1.2M-139.6%	-$513K
Investing Cash Flow	$5.0M+8972.6%	-$57K-1237.7%	-$4K+97.4%	-$164K+25.4%	-$219K-2129.0%	-$10K-1649.0%	$635-100.0%	$2.6M
Financing Cash Flow	-$3.1M-7444.3%	$42K+111.0%	-$384K+15.3%	-$453K-148.2%	-$182K-7207.1%	$3K+100.3%	-$974K-504.1%	-$161K
Dividends Paid	$8K	N/A	$8K0.0%	$8K-50.0%	$15K	N/A	$8K0.0%	$8K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GBCS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-3.8%+3.1pp	-6.9%+17.5pp	-24.4%-23.7pp	-0.7%+1.8pp	-2.5%-18.6pp	16.1%
Net Margin	-2.5%+3.7pp	-6.1%+4.7pp	-10.8%-4.9pp	-5.9%+1.8pp	-7.7%-21.8pp	14.1%
Return on Equity	N/A	N/A	N/A	-251.4%-178.9pp	-72.6%-159.2pp	86.6%
Return on Assets	-3.1%+4.1pp	-7.2%+2.5pp	-9.8%-4.1pp	-5.6%-0.8pp	-4.8%-11.2pp	6.4%
Current Ratio	0.30+0.1	0.18-0.1	0.27-0.5	0.72+0.0	0.68+0.4	0.26
Debt-to-Equity	-2.16+1.4	-3.54+5.0	-8.49-44.6	36.10+26.1	10.01+4.5	5.52
FCF Margin	3.5%+8.2pp	-4.7%-6.1pp	1.4%+2.7pp	-1.3%+1.4pp	-2.7%-11.1pp	8.3%

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-17.6%-13.5pp	-4.1%-1.3pp	-2.7%+1.6pp	-4.3%-0.3pp	-4.0%-3.1pp	-0.9%+10.8pp	-11.7%-3.7pp	-8.0%
Net Margin	90.9%+99.2pp	-8.3%-15.3pp	6.9%+9.9pp	-2.9%+3.3pp	-6.3%-0.7pp	-5.5%+10.5pp	-16.0%-24.3pp	8.3%
Return on Equity	2526.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	21.8%+24.2pp	-2.5%-4.7pp	2.3%+3.2pp	-0.9%+1.0pp	-1.9%-0.2pp	-1.7%+3.0pp	-4.7%-6.9pp	2.2%
Current Ratio	0.60+0.3	0.30+0.1	0.190.0	0.19-0.0	0.22+0.0	0.180.0	0.17-0.2	0.33
Debt-to-Equity	51.59+53.7	-2.16+1.1	-3.28-0.4	-2.92+0.2	-3.13+0.4	-3.54+0.3	-3.82+2.9	-6.71
FCF Margin	-37.1%-43.2pp	6.1%+3.5pp	2.5%+4.9pp	-2.3%-10.1pp	7.8%+11.9pp	-4.2%+8.1pp	-12.3%-6.9pp	-5.3%

Note: Shareholder equity is negative (-$6.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.30), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Veltex VLXC

$4.9M

Xcelerate Inc XCRT

$4.2M

Revitalist Lifes RVLWF

$5.4M

Healthlynked HLYK

$6.9M

Biocorrx Inc BICX

$11.0M

Frequently Asked Questions

What is Selectis Health Inc's annual revenue?

Selectis Health Inc (GBCS) reported $41.4M in total revenue for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Selectis Health Inc's revenue growing?

Selectis Health Inc (GBCS) revenue grew by 4.9% year-over-year, from $39.5M to $41.4M in fiscal year 2025.

Is Selectis Health Inc profitable?

No, Selectis Health Inc (GBCS) reported a net income of -$1.0M in fiscal year 2025, with a net profit margin of -2.5%.

What is Selectis Health Inc's EBITDA?

Selectis Health Inc (GBCS) had EBITDA of -$90K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Selectis Health Inc have?

As of fiscal year 2025, Selectis Health Inc (GBCS) had $1.0M in cash and equivalents against $13.4M in long-term debt.

What is Selectis Health Inc's operating margin?

Selectis Health Inc (GBCS) had an operating margin of -3.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Selectis Health Inc's net profit margin?

Selectis Health Inc (GBCS) had a net profit margin of -2.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Selectis Health Inc's free cash flow?

Selectis Health Inc (GBCS) generated $1.4M in free cash flow during fiscal year 2025. This represents a 177.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Selectis Health Inc's operating cash flow?

Selectis Health Inc (GBCS) generated $1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Selectis Health Inc's total assets?

Selectis Health Inc (GBCS) had $32.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Selectis Health Inc's capital expenditures?

Selectis Health Inc (GBCS) invested $444K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Selectis Health Inc have outstanding?

Selectis Health Inc (GBCS) had 3M shares outstanding as of fiscal year 2025.

What is Selectis Health Inc's current ratio?

Selectis Health Inc (GBCS) had a current ratio of 0.30 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Selectis Health Inc's debt-to-equity ratio?

Selectis Health Inc (GBCS) had a debt-to-equity ratio of -2.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Selectis Health Inc's return on assets (ROA)?

Selectis Health Inc (GBCS) had a return on assets of -3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Selectis Health Inc's debt-to-equity ratio negative or unusual?

Selectis Health Inc (GBCS) has negative shareholder equity of -$6.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Selectis Health Inc's Piotroski F-Score?

Selectis Health Inc (GBCS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Selectis Health Inc's earnings high quality?

Selectis Health Inc (GBCS) has an earnings quality ratio of -1.85x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Selectis Health Inc cover its interest payments?

Selectis Health Inc (GBCS) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Selectis Health Inc?

Selectis Health Inc (GBCS) scores 12 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.